a Adjusted for age, sex, BMI, race, asthma, COVPD, HF,
DM,ESRD Aldosterone antagonist and steroid use.
A total of 391 patients (18%) passed away within thirty days of
admission (256 (20%) subjects from the ACEI/ARB group and 135 (16%)
subjects from the non-ACEI/ARB group.
Although there was a statistically significant difference in the
COVID-19 mortality rates between the two groups in the unadjusted
logistic regression model (odds ratio= 1.31, 95% CI[1.01,1.54],
p-value= 0.03), the difference in the odd of COVID-19 mortality between
the two groups was not statistically significant in the adjusted model
(odds ratio= 1.20, 95% [(0.93, 1.54)], p-value= 0.14) (Table 3).
Table 3: Adjusted logistic regression model exploring the association
between the use of ACEI/ARBs and COVID-19 mortality.